Britzen-Laurent, N., Lipnik, K., Ocker, M., Naschberger, E., Schellerer, V.S., Croner, R.S., Vieth, M., Waldner, M., Steinberg, P., Hohenadl, C. and Sturzl, M. (2013) GBP-1 Acts as a Tumor Suppressor in Colorectal Cancer Cells. Carcinogenesis, 34, 153-162.
https://doi.org/10.1093/carcin/bgs310

has been cited by the following article:

• TITLE: hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance

  AUTHORS: Suzan Wadi, Aaron R. Tipton, Jill A. Trendel, Sadik A. Khuder, Deborah J. Vestal

  KEYWORDS: Guanylate-Binding Protein, Paclitaxel, Ovarian Cancer, Drug Resistance, GTPase, TUBB3

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.13, December 8, 2016

  ABSTRACT: Ovarian cancer is the gynecological cancer with the poorest prognosis. One significant reason is the development of resistance to the chemotherapeutic drugs used in its treatment. The large GTPase, hGBP-1, has been implicated in paclitaxel resistance in ovarian cell lines. Forced expression of hGBP-1 in SKOV3 ovarian cancer cells protects them from paclitaxel-induced cell death. However, prior to this study, nothing was known about whether hGBP-1 was expressed in ovarian tumors and whether its expression correlated with paclitaxel resistance. hGBP-1 is expressed in 17% of ovarian tumors from patients that have not yet received treatment. However, at least 80% of the ovarian tumors that recurred after therapies that included a taxane, either paclitaxel or docetaxel, were positive for hGBP-1. In addition, hGBP-1 expression predicts a significantly shorter progression-free survival in ovarian cancers. Based on these studies, hGBP-1 could prove to be a potential biomarker for paclitaxel resistance in ovarian cancer.